Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work (not exceeding fifteen (15) words), full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Signature of VDR miRNAs and Epigenetic Modulation of Vitamin D Signaling in Melanoma Cell Lines. S. ESSA, S. REICHRATH, U. MAHLKNECHT, M. MONTENARH, T. VOGT, J. REICHRATH *(Homburg/Saar, Germany)* .......................................................... 383


* Reviews (pages 1, 211, 223, 237, 271, 291, 299, 373)
* Review: The First Genome-wide View of Vitamin D Receptor Locations and their Mechanistic Implications. C. CARLBERG, S. SEUTER, S. HEIKKINEN (Kuopio, Finland; Luxembourg, Luxembourg) ...................... 271

Vitamin D Receptor Expression in Patients with Vulvar Cancer. D. SALEHIN, C. HAUGK, M. THILL, T. CORDES, M. WILLIAM, B. HEMMERLEIN, M. FRIEDRICH (Krefeld; Lübeck, Germany) ................... 283

* Review: The Roles of Cytochrome P450 Enzymes in Prostate Cancer Development and Treatment. T.C. CHEN, T. SAKAKI, K. YAMAMOTO, A. KITTAKA (Boston, MA, USA; Toyama; Tokyo; Sagamihara, Kanagawa, Japan) .................... 291

* Review: Vitamin D and Cellular Ca2+ Signaling in Breast Cancer. I.N. SERGEEV (Brookings, SD, USA) .... 299

Process Development for the Practical Production of Eldecalcitol by Linear, Convergent and Biomimetic Syntheses. N. KUBODERA, S. HATAKEYAMA (Shizuoka; Nagasaki, Japan) ...................................... 303

C15-functionalized 16-Ene-α,25-dihydroxyvitamin D3 is a New Vitamin D Analog with Unique Biological Properties. G. KUMAGAI, M. TAKANO, K. SHINDO, D. SAWADA, N. SAITO, H. SAITO, S. KAKUDA, K.-I. TAKAGI, M. TAKIMOTO-KAMIMURA, K. TAKENOUCHI, T.C. CHEN, A. KITTAKA (Sagamihara, Kanagawa; Hino, Tokyo, Japan; Boston, MA, USA) .................................................. 311


Association of Genetic Variants of the Vitamin D Receptor (VDR) with Cutaneous Squamous Cell Carcinomas (SCC) and Basal Cell Carcinomas (BCC): A Pilot Study in a German Population. K. KÖSTNER, N. DENZER, M. KORENG, S. REICHRATH, S. GRABER, R. KLEIN, W. TILGEN, T. VOGT, J. REICHRATH (Homburg; Kaiserslautern, Germany) .................................................................................................................... 327

Crystal Structure of a Vitamin D3 Analog, ZK203278, Showing Dissociated Profile. N. ROCHEL, D. MÓRAS (Illkirch, France) ......................................................................................................................... 335

Expression and Function of the Vitamin D Receptor in Malignant Germ Cell Tumour of the Testis. F. BREMMER, P. THELEN, T. POTTEK, C.L. BEHNES, H.J. RADZUN, S. SCHWEYER (Göttingen; Hamburg, Germany) ............................................................................................................................................................................. 341

Correlation of Prostaglandin Metabolizing Enzymes and Serum PGE2 Levels with Vitamin D Receptor and Serum 25(OH)2D3 Levels in Breast and Ovarian Cancer. T. CORDÉS, F. HOELLEN, C. DITTMER, D. SALEHIN, S. KÜMMEL, M. FRIEDRICH, F. KÖSTER, S. BECKER, K. DIEDRICH, M. THILL (Lübeck; Krefeld; Essen, Germany) ........................................................ 351

Influence of Calcitriol on Prostaglandin and Vitamin D-metabolising Enzymes in Benign and Malignant Breast Cell Lines. M. THILL, T. CORDES, F. HOELLEN, S. BECKER, C. DITTMER, S. KÜMMEL, D. SALEHIN, M. FRIEDRICH, K. DIEDRICH, F. KÖSTER (Lübeck; Krefeld; Essen, Germany) .............................................................. 359

Expression of Prostaglandin- and Vitamin D-metabolising Enzymes in Benign and Malignant Breast Cells. M. THILL, F. HOELLEN, S. BECKER, C. DITTMER, C. FISCHER, S. KÜMMEL, D. SALEHIN, M. FRIEDRICH, F. KÖSTER, K. DIEDRICH, T. CORDES (Lübeck; Krefeld; Essen, Germany) .............................................................. 367

* Review: Optimal Serum Calcidiol Concentration for Cancer Prevention. P. TUOHIMAA, Y.-R. LOU (Tampere; Helsinki, Finland) ........................................................................................................... 373

Contents continued on the preceding page

Vinorelbine versus Paclitaxel for Patients with Advanced Non–small Cell Lung Cancer (NSCLC) and a Performance Status of 2. P.A. KOSMIDIS, K. SYRIGOS, H.P. KALOFONOS, M.-A. DIMOPOULOS, D. SKARLOS, N. PAVLIDIS, I. BOUKOVINAS, D. BAFALOUKOS, D. PECTASIDES, C. BACOYIANNIS, G. FOUNTZILAS (Athens; Piraeus; Ioannina; Thessaloniki, Greece) .......................... 175


A Population-based Study of the Pattern of Terminal Care and Hospital Death in Patients with Non-small Cell Lung Cancer. C. NIEDER, T. TOLLÅLI, J NORUM, A. PAWINSKI, R.M. BREMNES (Bodo; Tromsø, Norway) .................................................................................................................. 189

Efficacy and Feasibility of Induction Chemotherapy and Radiotherapy plus Cetuximab in Head and Neck Cancer. M. RAMPINO, A. BACIGALUPO, E. RUSSI, M. SCHEMA, L. LASTRUCCI, C. IOtti, A. REALI, A. MUSU, V. BalcET, C. PIVA, S. BUSTREO, F. MUNOZI, R. RAGONA, R CORVÔ, U. RICARDI (Torino; Genova; Cuneo; ARezzo; Reggio Emilia, Italy) ........................................ 195

Analysis of Failures in Patients with FIGO Stage IIIc1-IIIc2 Endometrial Cancer. A. GADDUCCI, S. COSIO, M.G. FABRINI, M.E. GUERRIERI, C. GRECO, A.R. GENAZZANI (Pisa, Italy) .............. 201

Edited by J. Reichrath, M. Friedrich, Th. Vogt

Preface: Vitamin D and its Analogs in Cancer Prevention and Therapy. J. REICHRATH, M. FRIEDRICH, T. VogT (Homburg/Saar; Krefeld, Germany) ................................................................. 207


* Review: Ecological Studies of the UVB Vitamin D. Cancer Hypothesis. W.B. GRANT (San Francisco, CA, USA) ................................................................................................................................. 223

* Review: The Scots’ Paradox: Can Sun Exposure, or Lack of it, Explain Major Paradoxes in Epidemiology? O. GILLIE (London, UK) ........................................................................................................................................ 237


Determination of 1,25-dihydroxyvitamin D Concentrations in Human Colon Tissues and Matched Serum Samples. D. WAGNER, A.G. DIAS, K. SCHNABL, T. VAN DER KWAST, R. VIETH (Toronto, ON, Canada) .................................................................................................................. 259

Serum 25-Hydroxyvitamin D Levels in Patients with Vulvar Cancer. D. SALEHN, C. HAUGK, M. THILL, T. CORDES, D. HORNUNG, A. ABU-HECHLE, B. HEMMERLEIN, M. FRIEDRICH (Krefeld; Lübeck, Germany) .................................................................................................................. 265

* Indicates a paper that has been reviewed for its scientific quality and relevance.
Combinations of Resveratrol, Cisplatin and Oxaliplatin Applied to Human Ovarian Cancer Cells. M.U. NESSA, P. BEALE, C. CHAN, J.Q. YU, F. HUQ (Lidcombe; Concord, NSW, Australia) ......................... 53

Dual-mode Interaction between Quercetin and DNA-damaging Drugs in Cancer Cells. T. SAMUEL, K. FADLALLA, L. MOSLEY, V. KATKOORI, T. TURNER, U. MANNE (Tuskegee; Birmingham, AL, USA)...... 61

Mutated in Colorectal Cancer Protein Modulates the NFκB Pathway. N.D. SIGGLEKOW, L. PANGON, T. BRUMMER, M. MOLLOY, N.J. HAWKINS, R.L. WARD, E.A. MUGROVE, M.R.J. KOHONEN-CORISH (Sydney, Australia; Freiburg, Germany) ................................................................. 73

Combination of Glucan, Resveratrol and Vitamin C Demonstrates Strong Anti-tumor Potential. V. VETVICKA, J. VETVICKOVA (Louisville, KY, USA) .................................................. 81

The Hedgehog Pathway Inhibitor GDC-0449 Alters Intracellular Ca^{2+} Homeostasis and Inhibits Cell Growth in Cisplatin-resistant Lung Cancer Cells. F. TIAN, K. SCHRÖDL, R. KIEFL, R.M. HUBER, A. BERGNER (Munich, Germany) ............................................................................................. 89

Anticancer Effects of Synthetic Phosphoethanolamine on Ehrlich Ascites Tumor: An Experimental Study. A.K. FERREIRA, R. MENEGUELO, A. PEREIRA, O.M.R. FILHO, G.O. CHIERICE, D.A. MARIA (Sao Paulo; Sao Carlos; Belo Horizonte, Minas Gerais, Brazil) ............................................................................. 95

Trastuzumab Has Opposing Effects on SN-38-induced Double-strand Breaks and Cytotoxicity in HER2-positive Gastric Cancer Cells Depending on Administration Sequence. M. YAMADE, M. SUGIMOTO, M. NISHINO, T. UOTANI, S. SAHARA, M. IWAIZUMI, T. YAMADA, S. OSAWA, K. SUGIMOTO, H. MIYAJIMA, T. FURUTA (Hamamatsu, Japan) ................................................................................ 105

Somatostatin Receptor Subtype 2 A (SSTR2A) and HER2 Expression in Gastric Adenocarcinoma. A. ROMITI, R. DI ROCCO, M. MILIONE, L. RUO, V. ZIPARO, A. ZULLO, E. DURANTI, I. SARCINA, V. BARUCCA, C. D’ANTONIO, P. MARCHETTI (Rome; Milan, Italy) .................................................. 115

Inhibition of Cyclin D1 by shRNA Is Associated with Enhanced Sensitivity to Conventional Therapies for Head and Neck Squamous Cell Carcinoma. V. KOTHARI, R. MULHERKAR (Kharghar, Navi Mumbai, India) ..... 121

Naringin Inhibits Tumor Growth and Reduces Interleukin-6 and Tumor Necrosis Factor α Levels in Rats with Walker 256 Carcinosarcoma. C.A. CAMARGO, M.C.C. GOMES-MARCONDES, N.C. WUTZKI, H. AOYAMA (Sao Paulo, Brazil) ................................................................................................................. 129

Synthesis of Trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its Activity in Human Ovarian Tumour Models. N. DEQNAH, J.Q. YU, P. BEALE, K. FISHER, F. HUQ (Sydney, Australia) .................................................. 135

Circulating Transforming Growth Factor-β and Epidermal Growth Factor Receptor as Related to Virus Infection in Liver Carcinogenesis. R. DIVELLA, A. DANIELE, C. GADALETA, A. TUFARO, M.T. VENNERI, A. PARADISO, M. QUARANTA (Bari, Italy) ................................................................................. 141


Clinical Studies

Intense CD44 Expression Is a Negative Prognostic Factor in Tonsillar and Base of Tongue Cancer. D. LINDQUIST, A. ÅHLUND-RICHTER, M. TARIJAN, T. TOT, T. DALIANIS (Falun; Stockholm, Sweden) .... 153

Clinical Application of MAGE A1-6 RT-Nested PCR for Diagnosis of Lung Cancer Invisible by Bronchoscopy. K.-C. SHIN, E.Y. CHOI, J.H. CHUNG, C. JEON, K.H. LEE (Daegu, South Korea) ....... 163